GLO1 and diabetes mellitus: We examined skin sections from Trpa1+/+ and Trpa1−/− mice treated with the GLO-1 inhibitor or vehicle for 2 weeks to assess whether the hypersensitivities produced by inhibition of GLO-1 were accompanied by a loss of IENFs, similar to that seen in mouse models of diabetes.